New Phase III data show tiotropium Respimat effective across asthma severities

03-03-2014 Business Wire HealthComments (0)

BiotechnologyBoehringer IngelheimPharmaceuticalRespimat

New data presented today from large scale, Phase III studies show that once-daily tiotropium delivered via the Respimat inhaler was effective and well tolerated in patients across asthma severities.

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top